Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company
EVQLV Media
Seeking Alpha Breaks Story of Collaboration with Twist Bioscience
Seeking Alpha recently covered our work with Twist Bioscience on novel antibody discovery.
EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies
EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.
EVQLV’s Evolutionary Algorithm Explained
Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.
Andrew Satz on the Talent Finders Podcast
EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.
How far away is fully computational drug discovery?
Our CEO was recently asked how far away is fully computational drug discovery and development. This isn’t an easy question to answer and Andrew doesn’t provide an exact date. However, he does provide interesting insight into the progress we’ve made and the challenges ahead.
Beyond speed: The value of a computational approach to drug discovery
EVQLV CEO, Andrew Satz, explains that while speed is important, it can also be dangerous, and is certainly not the only reason we’ve chosen a computational approach to drug discovery.
How does EVQLV’s technology work?
Andrew Satz, CEO of EVQLV, explains how our technology works, with specific attention to our progress on COVID-19.
Andrew Satz discusses AI, Coronavius and EVQLV’s Mission on the M2 Techcast
EVQLV’s very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn’t artificial intelligence, the application of AI, and our mission at EVQLV.
Watch our event with BioIDEA: Biotech vs COVID-19
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
What we do and how we do it
EVQLV uses artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with applied external pressures to generate candidates. There’s a lot more to it, but we thought you might enjoy a taste of our “secret sauce.”
Combatting COVID-19: 21 Innovative Efforts
We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.